Tofersen
托夫生SOD1 antisense oligonucleotide newly added to the 2026 Commercial Health Insurance Innovative Drug List (#25) for adult SOD1-mutated ALS.
China Approval (NMPA)
Approved- Approval Number(s)
- 国药准字HJ20240102
- Initial Approval Date
- Sep 26, 2024
- Notice Published
- Oct 8, 2024
- MAH
- Biogen MA Inc. (Biogen MA Inc.)
- Approved Scope
- Conditional approval for adult patients with amyotrophic lateral sclerosis (ALS) associated with a mutation in the SOD1 gene.
National Reimbursement
Not ListedNot included in the 2025 or 2026 National Reimbursement Drug List (basic medical insurance).
Commercial Insurance List
Announced · Effective Jan 1, 2027- 2026 List Entry
- #25 · 凯盛迪
- Validity Period
- 2027-01-01 to 2028-12-31
- MAH / Authorized Entity
- Biogen MA Inc. · 渤健生物科技(上海)有限公司
- Listed Indication Scope
- Adult patients with amyotrophic lateral sclerosis (ALS) associated with a mutation in the superoxide dismutase 1 (SOD1) gene.
Catalog inclusion only. Actual reimbursement depends on individual commercial health insurance policy contracts.
Approved Products, Dosage Forms & Approval Numbers
1 verified NMPA record| Approval No. | Dosage Form & Strength | Event & Scope | Approval / Notice Date | MAH & Source |
|---|---|---|---|---|
| 国药准字HJ20240102 | Injection (注射液) 15ml:0.1g (100mg) | Initial Approval Conditional approval for adult patients with amyotrophic lateral sclerosis (ALS) associated with a mutation in the SOD1 gene. 用于治疗携带超氧化物歧化酶1(SOD1)基因突变的肌萎缩侧索硬化(ALS)成人患者(附条件批准)。 | Approved: 2024-09-26 Published: 2024-10-08 | Biogen MA Inc. |
Change Timeline
- (2027-01-01)Commercial List· Catalog published: Nov 14, 2026
2026 Commercial List · Newly Added (#25)
Adult patients with amyotrophic lateral sclerosis (ALS) associated with a mutation in the superoxide dismutase 1 (SOD1) gene.
Chinese original: 本品用于治疗携带超氧化物歧化酶1(SOD1)基因突变的肌萎缩侧索硬化(ALS)成人患者。
NHSA · PDF p.4Verified 2026-11-20 - (2024-09-26)NMPA Approval· Notice published: Oct 8, 2024
NMPA Initial Marketing Approval (国药准字HJ20240102 · 15ml:0.1g (100mg))
Conditional approval for adult patients with amyotrophic lateral sclerosis (ALS) associated with a mutation in the SOD1 gene.
Chinese original: 用于治疗携带超氧化物歧化酶1(SOD1)基因突变的肌萎缩侧索硬化(ALS)成人患者(附条件批准)。
NMPA · NMPA Registration HJ20240102Verified 2026-11-21
Verified Names & Aliases
Every English INN, Chinese generic name, brand name, and R&D code is recorded with its source.
Primary Sources for This Record
- NHSAPublished 2026-11-14商业健康保险创新药品目录(2026年)Retrieved 2026-11-20
- NMPA国家药监局药品监管动态Retrieved 2026-11-20
- WHO世界卫生组织国际非专利药名(INN)指南Retrieved 2026-11-20